The Kochi-based Amrita Centre for Nanosciences and Molecular Medicine on 22 September 2013 announced it’s newly developed a nano-medicine for drug-resistant blood cancer.
This invention expected to dramatically improve the treatment of drug-resistant Chronic Myelogenous Leukemia (CML), when used in combination with Imatinib, the standard drug for the disease.
In another significant invention, the institute has devised a mechanism that can effectively prevent recurrence of glioma or brain tumour. This deadly disease affects about four out of every 100000 people in India. The life expectancy of high-grade glioma patients is about one to two years.
Chronic Myelogenous Leukemia (a form of blood cancer) annually affects approximately two out of every 100000 Indians. Almost 40 per cent of these cases are resistant to Imatinib. For such patients, treatment options are extremely limited.
When: 22 September 2013
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.